Effectiveness and Safety of Polatuzumab Vedotin Plus an Anti‐CD20 Monoclonal Antibody (Rituximab or Obinutuzumab) and Zanubrutinib in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
In our study, patients derived clinical benefit after receiving Pola-ZR/G compared to TST; the regimens had a tolerable safety profile in patients with R/R DLBCL.
Authors
- Yian Zhang (ORCID: https://orcid.org/0000-0002-4033-211X)
- Ling Yuan (ORCID: https://orcid.org/0000-0001-7351-5097)
- Yuhong Ren (ORCID: https://orcid.org/0000-0003-0330-4125)
- Jing Li (ORCID: https://orcid.org/0009-0003-6463-2082)
- Peng Liu (ORCID: https://orcid.org/0000-0002-9639-6606)
- Wei‐Guang Wang (ORCID: https://orcid.org/0000-0003-3395-767X)
- Zhixiang Cheng (ORCID: https://orcid.org/0009-0002-0984-4771)
- Zhimei Wang (ORCID: https://orcid.org/0000-0003-3387-6765)
- Xuejiao Zhang (ORCID: https://orcid.org/0000-0001-9544-0073)
- Luya Cheng
- Jingli Zhuang
Institutions
- Sun Yat-sen University (CN)
- Fudan University (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1002/cam4.71162
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shanghai